Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | ACLY | P53396 | 9/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7803343 | 0.92 | MAPT (0.69) | KMT2ALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL7797547 | 0.89 | KMT2A (0.64) | KMT2ALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL7806243 | 0.89 | KMT2A (0.60) | KMT2ALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL7811207 | 0.87 | LMNA (0.55) | KMT2ALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL7798880 | 0.85 | MAPT (0.55) | KMT2ALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL7805723 | 0.85 | CNR1 (0.58) | KMT2ALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL7805558 | 0.84 | IDH2 (0.61) | KMT2ALMNAMAPTMEN1MAPK1 | |
| SCHEMBL7804129 | 0.83 | PFKFB3 (0.60) | KMT2ALMNAMAPTMEN1MAPK1 | |
| SCHEMBL7806992 | 0.83 | CNR1 (0.58) | KMT2ALMNAMAPTKDM4EALDH1A1 | |
| SCHEMBL23229426 | 0.82 | ALDH1A1 (1.00) | KMT2ALMNAMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | KMT2A 2144/4885LMNA 2594/4885MAPT 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.